Advanced Gene Editing with CRISPR is a 3 day live remote workshop designed for researchers with entry level experience in CRISPR/Cas9 technology seeking a more in-depth immersion in state-of-art CRISPR [….]
Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug [….]
This five day live remote workshop is ideal for bench and research scientists who are looking for a solid foundation in RNA-Seq, from application, experimental design and sample preparation to [….]
This rigorous three day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. hands-on introduction to gene editing iPSCs using CRISPR/Cas9. [….]
American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.
Discovery Labs suburban Philadelphia campus gained a new tenant, the University of Pennsylvania Gene Therapy Program (GTP), which focuses on the development of AAV-based gene therapies for rare and orphan genetic diseases with high unmet needs.
This remote rigorous three-day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. laboratory introduction to CRISPR toolkit. Taught by active [….]
Frederick’s RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium
RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. RoosterGEM, abbreviated for Rooster Genetic Engineering Medium, complements RoosterBio’s hMSC cell engineering system to offer a new and streamlined path for discovery, preclinical, and applied product development research – faster than ever before.
Philadelphia’s soaring life sciences commercial real estate market is being driven by the combination of strong demand for advanced lab and manufacturing facilities and near record low vacancy rates.
Gyroscope Therapeutics, a gene therapy company developing treatments for eye diseases, filed a Form F-1 with the U.S. Securities and Exchange Commission announcing its intention to begin selling American Depository Shares on the Nasdaq Exchange under the ticker symbol “VISN.” At the time of its filing this week, Gyroscope said it has not yet set the pricing terms for its stock. The $100 million is a placeholder figure. Based on positive clinical activity, and a recent financing round, the company is likely to raise significantly more than $100 million.